达仁堂: 达仁堂2025年第五次董事会决议公告

Core Points - The company held its fifth board meeting of 2025 on August 13, 2025, with all nine directors present, complying with relevant laws and regulations [1] - The board approved the 2025 semi-annual report under Chinese standards and the interim report under international standards, with unanimous support [1] - A special report on the use of raised funds was also approved, receiving full agreement from the board [1] - The board reviewed and approved a risk assessment report regarding Tianjin Pharmaceutical Group Finance Co., Ltd., with unanimous support [1] - The board approved a proposal to purchase liability insurance for the company and its directors, supervisors, and senior management, which will be submitted to the shareholders' meeting for approval [2] - The board also approved amendments to the general authorization for related party transactions according to Singapore Exchange rules, which will be submitted to the shareholders' meeting for approval [2]